Moreover, the impact of ICP expression on MDS prognosis was assessed in a recent study, which evaluated the mutation burden in genes coding for ICP molecules (LAG-3, CTLA-4, B7H3, PD-1, PD-L1, etc.). This evidence concerns the gene CD274 and myelodysplastic syndrome.